- Home
- SHLS vs CGEM Comparison
SHLS vs CGEM Comparison
Compare SHLS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- CGEM
- Stock Information
- Founded
- SHLS 1996
- CGEM 2016
- Country
- SHLS United States
- CGEM United States
- Employees
- SHLS N/A
- CGEM N/A
- Industry
- SHLS Semiconductors
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- CGEM Health Care
- Exchange
- SHLS Nasdaq
- CGEM Nasdaq
- Market Cap
- SHLS 951.6M
- CGEM 955.5M
- IPO Year
- SHLS 2021
- CGEM 2021
- Fundamental
- Price
- SHLS $4.56
- CGEM $13.86
- Analyst Decision
- SHLS Buy
- CGEM Strong Buy
- Analyst Count
- SHLS 18
- CGEM 7
- Target Price
- SHLS $12.14
- CGEM $31.67
- AVG Volume (30 Days)
- SHLS 5.3M
- CGEM 491.7K
- Earning Date
- SHLS 11-12-2024
- CGEM 11-07-2024
- Dividend Yield
- SHLS N/A
- CGEM N/A
- EPS Growth
- SHLS N/A
- CGEM N/A
- EPS
- SHLS 0.19
- CGEM N/A
- Revenue
- SHLS $422,657,000.00
- CGEM N/A
- Revenue This Year
- SHLS N/A
- CGEM N/A
- Revenue Next Year
- SHLS $17.85
- CGEM N/A
- P/E Ratio
- SHLS $23.49
- CGEM N/A
- Revenue Growth
- SHLS N/A
- CGEM N/A
- 52 Week Low
- SHLS $4.53
- CGEM $7.64
- 52 Week High
- SHLS $17.50
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- SHLS 37.00
- CGEM 35.59
- Support Level
- SHLS $4.64
- CGEM $15.37
- Resistance Level
- SHLS $5.36
- CGEM $17.50
- Average True Range (ATR)
- SHLS 0.44
- CGEM 1.08
- MACD
- SHLS -0.08
- CGEM -0.13
- Stochastic Oscillator
- SHLS 1.82
- CGEM 3.45
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.